“All aspects of the VIGILA, TILDA and CELERITY leads are carefully designed to enhance ease of use and handling without compromising electrical performance and safety”
Cardiovascular company Sorin Group has announced CE Mark approval and commercial launch for a comprehensive new range of pacing, defibrillation and left ventricular leads. According to the company the new , TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular lead families are designed for safety and long term reliability and offer multiple implant options to accommodate patients’ needs and physicians’ preferences.
All the product families benefit from flexible silicone lead body, steroid eluting tips that reduce inflammation and iridium fractal coated electrodes with proven electrical performance. Each lead family then possesses its own additional features:
- TILDA pacing leads are flexible from the lead connector to the distal tip, giving physicians the instant sensation of familiarity at implant along with predictable outcomes.
- VIGILA defibrillation leads feature a symmetrical lead body and thick outer insulation. Convex shock coils embedded in silicone insulation are engineered to minimize tissue in-growth.
- CELERITY left ventricular leads have a flexible co-radial body intended to improve control and handling. The three pre-shaped fixation alternatives are designed to facilitate access and ensure stability in targeted pacing sites regardless of patients’ challenging coronary venous anatomies.
According to the company, its TILDA, VIGILA and CELERITY leads’ possess lasting performance and quality, combined with Sorin Group’s unique algorithms, in order to provide reliable and individualised therapies for patients.
“These leads are great additions to the current Sorin Group portfolios,” said Dr David Le Froy, Consultant Cardiologist, Hammersmith Hospital, Imperial College Healthcare Trust, London, UK. “All aspects of the VIGILA, TILDA and CELERITY leads are carefully designed to enhance ease of use and handling without compromising electrical performance and safety,” he added.
“With these new options, more patients will benefit from Sorin’s unique therapies such as SafeR™, PARAD+™ BTO™, and SonR®, some of the most efficient algorithms on the market today.”
“Instilling greater clinical confidence by delivering high performance, reliability and value to our customers is at the core of everything we do,” commented Stefano Di Lullo, Sorin Group, President of the CRM Business Unit. “This comprehensive lead portfolio complements our state-of-the-art implantable devices perfectly and will offer significant clinical benefits to each individual patient.”
Source: Sorin Group